Abeona Therapeutics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Abeona Therapeutics Inc. has issued its 2026 proxy statement detailing proposals for director elections, executive compensation, and an increase in equity incentive plan shares.
NASDAQ
Abeona Therapeutics will hold its annual stockholders meeting virtually on May 19, 2025, to vote on director elections, executive compensation, and auditor ratification.
NASDAQ
Abeona Therapeutics is asking shareholders to approve an increase in the number of shares reserved for issuance under its 2023 Equity Incentive Plan from 3,200,000 to 8,400,000 shares.
NASDAQ
Abeona Therapeutics is asking stockholders to approve an increase in shares reserved for issuance under its 2023 Equity Incentive Plan from 1.7 million to 3.2 million shares at the upcoming annual meeting.